Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Average Recommendation of “Buy” from Brokerages

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) have been assigned an average rating of “Buy” from the six brokerages that are currently covering the firm, Marketbeat reports. Six analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $8.50.

PYXS has been the subject of a number of research reports. Leerink Partnrs restated an “outperform” rating on shares of Pyxis Oncology in a research note on Tuesday, January 23rd. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $7.00 target price on shares of Pyxis Oncology in a research note on Friday, March 22nd. HC Wainwright reissued a “buy” rating and set a $7.00 price target on shares of Pyxis Oncology in a research note on Wednesday, April 10th. BTIG Research started coverage on shares of Pyxis Oncology in a research report on Friday, February 9th. They issued a “buy” rating and a $8.00 price objective for the company. Finally, SVB Leerink started coverage on Pyxis Oncology in a research report on Tuesday, January 23rd. They issued an “outperform” rating and a $12.00 price objective on the stock.

Institutional Trading of Pyxis Oncology

Institutional investors have recently bought and sold shares of the business. abrdn plc bought a new position in shares of Pyxis Oncology in the 4th quarter worth $1,275,000. Vestal Point Capital LP bought a new position in Pyxis Oncology during the fourth quarter worth about $792,000. Decheng Capital LLC acquired a new position in shares of Pyxis Oncology during the 4th quarter worth about $588,000. Decheng Capital Management III Cayman LLC bought a new stake in shares of Pyxis Oncology in the 3rd quarter valued at about $650,000. Finally, Cable Car Capital LLC acquired a new stake in shares of Pyxis Oncology in the 4th quarter valued at approximately $111,000. Institutional investors and hedge funds own 39.09% of the company’s stock.

Pyxis Oncology Stock Performance

NASDAQ:PYXS opened at $4.31 on Thursday. Pyxis Oncology has a 12 month low of $1.35 and a 12 month high of $6.85. The company’s 50-day moving average price is $5.04 and its two-hundred day moving average price is $3.37.

Pyxis Oncology (NASDAQ:PYXS) last announced its earnings results on Thursday, March 21st. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.16. As a group, analysts forecast that Pyxis Oncology will post -0.85 EPS for the current fiscal year.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody, which is in Phase 1 clinical trial for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma.